1935 ⎘
Rearing or breeding animals, not otherwise provided for; New breeds of animals; New breeds of vertebrates; Genetically modified vertebrates, e.g. transgenic Knockout animals
Fumarylacetoacetate hydrolase (Fah)-deficient pigs and uses thereof
#602Anti-tumor properties of Dickkopf 3b
#603Methods and compositions for the targeted modification of a mouse genome
#604Use of antagonists targeting metallothionein to treat intestinal inflammation
#605TRANSGENIC MOUSE MODELS FOR MC4R
#606Methods of modulating thrombocytopenia and modified transgenic pigs
#607Normalization of the enterohepatic circulation in animals with a chimeric humanized liver
#608Methods and compositions for the treatment of insulin-associated medical conditions
#609Porcine Animals Lacking Any Expression of Functional Alpha 1,3 Galactosyltransferase
#610Genetically modified non-human animals and methods relating to innate immune system response detection
#611PHARMACEUTICAL COMPOSITION FOR VIRAL TREATMENT, AND METHOD FOR SCREENING ANTIVIRAL AGENT
#612Production of fertile XY female animals from XY ES cells
#613GENETICALLY MODIFIED NON-HUMAN MAMMALS AND CELLS
#614GENETICALLY MODIFIED RAT MODELS FOR PAIN
#615GENETICALLY MODIFIED RAT MODELS FOR PHARMACOKINETICS
#616IncRNA-knockout mice
#617Activity modulator, medicinal agent comprising same, use of CD300A gene-deficient mouse, and anti-CD300A antibody
#618Animal models and therapeutic molecules
#619Animals, repertoires and methods
#620Mito-Ob: a transgenic mouse model for obesity
#621Inflammation in vivo model
#622Isolated cells from humanized FcγR mice
#623Method and cells for the production of viral vaccines
#624Transgenic transchromosomal rodents for making human antibodies
#625Non human animal model for ulcerative colitis and its main complications
#626GENETICALLY STERILE ANIMALS
#627SWINE GENETICALLY MODIFIED WITH SPECIFICITY FOR LDL-R KNOCKOUT
#628TRANSGENIC MOUSE MODEL FOR DEVELOPING ENZYME REPLACEMENT THERAPY FOR IDURONATE-2-SULFATASE DEFICIENCY SYNDROME
#629ORGAN REGENERATION METHOD UTILIZING iPS CELL AND BLASTOCYST COMPLEMENTATION
#630Methods and compositions for generating a mouse
#631Transgenic Non-Human Assay Vertebrates, Assays and Kits
#632TRANSGENIC BIRDS THAT PRODUCE CHIMERIC HUMAN IMMUNOGLOBULINS
#633TRANSGENIC CHICKENS WITH AN INACTIVATED ENDOGENOUS GENE LOCUS
#634Method for producing model animal, and model animal
#635Mice that make heavy chain antibodies
#636Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
#637Transgenic pig models of cystic fibrosis
#638Animal models of duchenne muscular dystrophy
#639Non Human Animal Models for Increased Retinal Vascular Permeability
#640Low affinity FCGR deficient mice
#641WDR13 as a novel biomarker useful for treating diabetes and cancer
#642Humanized Fc gamma R mice
#643Animal models and therapeutic molecules
#644Genetically modified non-human animals and methods of use thereof
#645Transgenic non-human animal model of neurodegenerative disease
#646CONTROL OF SEXUAL MATURATION IN ANIMALS
#647hnRNP A1 knockout animal model and use thereof
#648Animal models and therapeutic molecules
#649DOUBLE KNOCKOUT (GT/CMAH-KO) PIGS, ORGANS AND TISSUES
#650Porcine reproductive and respiratory syndrome virus resistant animals
#651Mouse for predicting a behavior of drugs in humans
#652Transgenic chicken comprising an inactivated immunoglobulin gene
#653Tetraspanin CD82 as a Diagnostic and/or Therapeutic Module for Xenograft Recognition and/or Rejection
#654Efficient protein expression in vivo using modified RNA (MOD-RNA)
#655Epo knockout GFP anemic mouse
#656Elimination of N-glycolylneuraminic acid from animal products for human use
#657Genetically engineered mouse model for autism spectrum disorder having deletion of gene and use thereof
#658Methods for treating metabolic syndrome with Cthrc1 polypeptide
#659Transgenic mouse having a genome comprising a homozygous disruption of the endogenous MFN2 gene expression in the dopaminergic neurons
#660Antibody production
#661Methods for treating disorders that involve immunoglobulin A
#662Novel Inflammation to vivo model
#663Mouse models carrying a knock-out mutation of the QPCTL-gene
#664ANF-RGC in-gene knock-out animal
#665Micro-RNA family that modulates fibrosis and uses thereof
#666Micro-RNA family that modulates fibrosis and uses thereof
#667Substances and compositions for enhancing DNA repair and methods of use
#668Indoleamine 2,3-Dioxygenase-2
#669Hairless NOD scid mouse
#670Animal models of atherosclerosis
#671ORGANISMS HOMOZYGOUS FOR TARGETED MODIFICATION
#672Micro-RNA family that modulates fibrosis and uses thereof
#673Fumarylacetoacetate hydrolase (fah)-deficient pigs and uses thereof
#674Model Animal for Studying Hair Growth Cycle
#675Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication
#676Implantation of a cardiac xenograft from a B4GALNT2KO and GTKO transgenic pig to reduce immunogenicity
#677Method for treating cancer with an antibody to CD223 protein
#678NRIP knockout mice and uses thereof
#679Methods for inhibiting hematopoiesis with a hedgehog antagonist
#680hnRNP A1 KNOCKOUT ANIMAL MODEL AND USE THEREOF
#681Screening of drug for attention deficit hyperactive disorder by using GIT1 knock-out mice as a novel ADHD mouse model
#682CD4 T-cells and CD8zeta cells involved in mammalian host response to epithelial cell infections and uses thereof
#683Genetically altered animal specimen and related methods
#684Mouse λ light chain locus
#685Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
#686Transgenic mouse homozygous for chimeric IgH locus
#687Methods and means for increasing resistance to cell damage
#688Elimination of N-glycolylneuraminic acid from animal products for human use
#689Treatment of Pompe's Disease
#690Identification of micro-RNAs involved in neuromuscular synapse maintenance and regeneration
#691Methods and compositions to modulate antiviral and immune activity responses
#692Lysyl oxidase-like 1 (LOXL1) and elastogenesis
#693METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS
#694Compositions and methods for preparing recombinant MG53 and methods for optimizing same
#695METHODS FOR TREATING DISEASES
#696METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION
#697KNOCK DOWN MODEL OF DICKKOPF HOMOLOGUE 3 (Dkk3) FOR ASSESSING ROLE OF SAID Dkk3 IN SPERMATOGENESIS AND SEX REVERSAL
#698MOUSE MODEL FOR AVM
#699Tissue Products Derived From Animals Lacking Any Expression of Functional Alpha 1, 3 Galactosyltransferase
#700Chimeric rat produced using rat embryonic stem cells in the presence of an ES cell differentiation suppressant
#701STROMAL INTERACTING MOLECULE KNOCKOUT MOUSE AND USES THEREOF
#702GLYCINE N-METHYLTRANSFERASE (GNMT) ANIMAL MODEL AND USE THEREOF
#703Low affinity FcγR deficient mice
#704Porcine Animals Lacking Any Expression of Functional Alpha 1,3 Galactosyltransferase
#705ACE2 activation for treatment of heart, lung and kidney disease and hypertension
#706JNK3 MODULATORS AND METHODS OF USE
#707Methods of modulating apoptosis by administration of relaxin agonists or antagonists
#708MO-1 conditional knock-out non-human animal and uses thereof
#709GENETICALLY MODIFIED ANIMALS AND METHODS FOR MAKING THE SAME
#710Composition comprising rna derived from lactic acid bacterium as effective component
#711Methods and materials for producing transgenic artiodactyls
#712Novel gene disruptions, compositions and methods relating thereto
#713SorCS1 for the treatment of obesity
#714Methods of identifying candidate compounds of the human G protein-coupled receptor, GPR50, as modulators of body mass or adiposity
#715ANIMAL MODELS AND THERAPEUTIC MOLECULES
#716COMPOSITIONS RELATING TO A PHOSPHOPROTEIN AND METHODS OF USE
#717UBIQUITIN INTERACTING MOTIF PEPTIDES AS CANCER THERAPEUTICS
#718Common Light Chain Mouse
#719METHOD FOR GENOME EDITING
#720METHOD OF TREATING NEURODEGENERATIVE DISEASE
#721GLOBAL NAV1.7 KNOCKOUT MICE AND USES
#722Compositions and Methods for Preventing or Treating Influenza Virus Infection
#723PNMT as a novel marker for progenitor cells
#724DOUBLE MUTANT MOUSE AND CELL LINES
#725TRANSGENIC MOUSE MODEL FOR DEVELOPING ENZYME REPLACEMENT THERAPY FOR IDURONATE-2-SULFATASE DEFICIENCY SYNDROME
#726Animal models of neurological disorders
#727Diagnosis of depression
#728Genetically modified rat models for severe combined immunodeficiency (SCID)
#729Profiling fragments of elastic fibers and microfibrils as biomarkers for disease
#730Novel PRO1199 gene disruptions, and methods relating thereto
#731ANIMAL MODELS AND THERAPEUTIC MOLECULES
#732Method of predicting a behavior of one or more drugs
#733GENOME EDITING OF GENES INVOLVED IN ADME AND TOXICOLOGY IN ANIMALS
#734GENOMIC EDITING OF GENES INVOLVED IN MACULAR DEGENERATION
#735SorCS1-like agent for use in the treatment of insulin resistance and diseases related thereto
#736Genetically Modified Rat Models for Pain
#737Method for preventing and treating cardiovascular diseases with BRCA1
#738NON HUMAN ANIMAL MODELS FOR INCREASED RETINAL VASCULAR PERMEABILITY
#739Method of Genetically Altering and Producing Allergy Free Cats
#740DHX36 / RHAU KNOCKOUT MICE AS EXPERIMENTAL MODELS OF MUSCULAR DYSTROPHY
#741DNA FRAGMENT AND PHARMACEUTICAL COMPOSITION
#742TRUNCATED ACTIVIN TYPE II RECEPTOR AND METHODS OF USE
#743Indoleamine 2,3-dioxygenase-2 antibodies
#744Rat having a disrupted immunoglobulin gene
#745Immunocompromised Ungulates
#746Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis
#747Immunoadjuvant composition and use thereof
#748Mouse model for pompe disease and methods of use thereof
#749Use of Guanylyl Cyclase C Agonists to Suppress Appetite
#750Caveolin 1-reporter protein knock-in mouse
#751METHOD OF EXPANDING HUMAN HEPATOCYTES IN VIVO
#752RSPONDIN-3 INHIBITION IN BONE DISORDERS
#753The Role of p110 delta Signaling in Morbidity and Lung Pathology Induced by Influenza Virus Infection
#754GENOMIC EDITING OF GENES INVOLVED WITH PARKINSONS DISEASE
#755NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO
#756Treatment and Prevention of Chronic Asthma Using Antagonists of Integrin AlphavBeta6
#757Methods of identifying agents that modulate phenotypes related to disruptions, of a gene encoding PRO235 polypeptide
#758ANIMAL MODEL FOR PARKINSON'S DISEASE
#759Non-human animal model for amyotrophic lateral sclerosis (ALS) with loss-of-TDP-43 function
#760Targets for treatment of hypercholesterolemia
#761ANTIBODY PRODUCTION
#762Production of fertile XY animals from XY ES cells
#763CALCIUM SENSOR STIM1 AND THE PLATELET SOC CHANNEL ORAI1 (CRACM1) ARE ESSENTIAL FOR PATHOLOGICAL THROMBUS FORMATION
#764Human CTLA-4 antibodies and their uses
#765Use of VEGF and homologues to treat neuron disorders
#766MG53 COMPOSITIONS AND METHODS OF USE
#767Treatment and Prevention of Chronic Asthma Using Antagonists of Integrin AlphavBeta6
#768MG53 COMPOSITIONS AND METHODS OF USE
#769Mouse model for depression, schizophrenia and alzheimer's disease and the use thereof
#770Genetically modified non-human mammals and cells
#771Screening methods for compounds useful for treating pancreatic dysfunction
#772Signatures and PCDeterminants Associated with Prostate Cancer and Methods of Use Thereof
#773Method for selective control of helper T cell function
#774ORGAN REGENERATION METHOD UTILIZING iPS CELL AND BLASTOCYST COMPLEMENTATION
#775Humanized FcgR mice
#776Methods for treating osteoporosis with anti-IL-20 receptor antibodies
#777Novel gene disruptions, compositions and methods relating thereto
#778COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATING TO OXIDATIVE STRESS
#779Organisms homozygous for targeted modification
#780INHIBITING OBESITY PROGRESSION BY INHIBITING ADIPOCYTE DIFFERENTIATION WITH A PRE-ADIPOCYTE AUTOPHAGY INHIBITOR
#781TRANSGENIC ANIMALS AND USES THEREOF
#782TIKI1 AND TIKI2, WNT INHIBITORS
#783Potential Prognostic Markers and Therapeutic Targets for Neurological Disorders
#784G-Protein Coupled Receptor 30 (GPR30) transgenic animals as a model for cardiovascular diseases
#785Evaluation/screening method for diseases associated with D-amino acid utilizing DAO1-/-mouse
#786NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO
#787METHODS AND MATERIALS FOR PRODUCING TRANSGENIC ARTIODACTYLS
#788ARTERY- AND VEIN-SPECIFIC PROTEINS AND USES THEREFOR
#789Common light chain mouse
#790Peptides that target dorsal root ganglion neurons
#791CISD2-Knockout Mice and Uses Thereof
#792NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO
#793MODULATION OF GM98 (MRF) IN REMYELINATION
#794NOVEL GPR101 TRANSGENIC MICE AND METHODS OF USE THEREOF
#795TRANSGENIC ANIMALS EXPRESSING ANTIBODIES SPECIFIC FOR GENES OF INTEREST AND USES THEREOF
#796Vitamin K Epoxide Recycling Polypeptide VKORC1, a Therapeutic Target of Coumarin and Their Derivatives
#797Humanized FcγR mice
#798Heparanase deficient non-human mammals
#799Method for modifying chromosomes
#800Mice that make heavy chain antibodies
#801Genetically Modified Rat Models for Pharmacokinetics
#802TRANSGENIC MICE HAVING A HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) PHENOTYPE, EXPERIMENTAL USES AND APPLICATIONS
#803DEFICIENCY IN THE HISTONE DEMETHYLASE JHDM2A RESULTS IN IMPAIRED ENERGY EXPENDITURE AND OBESITY
#804Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
#805METHODS AND COMPOSITIONS FOR TREATING FUS1 RELATED DISORDERS
#806ANIMALS WITH REDUCED BODY FAT AND INCREASED BONE DENSITY
#807knockout mice and elucidation of association of with early onset degenerative joint disease and role as a tumor suppressor
#808Ultra-small RNAs as toll-like receptor-3 antagonists
#809Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
#810Mouse λ light chain locus
#811Methods of identifying agents that ameliorate or modulate effects of PRO1328 gene disruptions
#812Allergic disease model animals
#813USE OF P27KIP1 FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
#814Transgenic mouse comprising a disrupted Fibulin-4 gene as a model for cardiovascular disease
#815Expression of Xenogenous (Human) Immunoglobulins in cloned, transgenic ungulates
#816Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses and applications
#817Methods of inhibiting tumor cell proliferation
#818NOVEL PRO258 GENE DISRUPTIONS, AND METHODS RELATING THERETO
#819Methods of modulating apoptosis by administration of relaxin agonists or antagonists
#820Chd5 is a novel tumor suppressor gene
#821TAJ in Neuronal Function
#822HEAT SHOCK PROTEIN DEFICIENCIES AS MODEL SYSTEMS FOR BRAIN PATHOLOGY AND CANCER
#823CANDIDATE GENES AND BLOOD BIOMARKERS FOR BIPOLAR MOOD DISORDER, ALCOHOLISM AND STRESS DISORDER
#824Substances and compositions for enhancing DNA repair and methods of use
#825Promoter-regulated differentiation-dependent self-deleting cassette
#826miRNA-regulated differentiation-dependent self-deleting cassette
#827Organisms homozygous for targeted modification
#828Multi-transgenic pigs for diabetes treatment
#829Genetically Modified Rat Models for Drug Metabolism
#830Mosaic knockout mouse tumor models and methods or use
#831Truncated activin type II receptor and methods of use
#832METHODS OF MODULATING THE ORGANIC SOLUTE AND STEROID TRANSPORTER (OSTalpha-OSTbeta) ACTIVITY AND TREATING ASSOCIATED CONDITIONS
#833COMPOSITIONS AND METHODS FOR CANCER GENE DISCOVERY
#834Transgenic Animal Model of Cancer and Methods of Use
#835Diagnosis and treatment of autism using CD38
#836Therapeutic or prophylactic agent, detection method and detection agent for metabolic syndrome, and method for screening of candidate compound for therapeutic agent for metabolic syndrome
#837BOVINE GENOME EDITING WITH ZINC FINGER NUCLEASES
#838EQUINE GENOME EDITING WITH ZINC FINGER NUCLEASES
#839FELINE GENOME EDITING WITH ZINC FINGER NUCLEASES
#840GENOMIC EDITING OF GENES INVOLVED IN ALZHEIMER'S DISEASE
#841GENOME EDITING OF COGNITION RELATED GENES IN ANIMALS
#842GENOME EDITING OF ABC TRANSPORTERS
#843GENOME EDITING OF GENES ASSOCIATED WITH SCHIZOPHRENIA IN ANIMALS
#844GENOMIC EDITING OF GENES INVOLVED IN TUMOR SUPPRESSION IN ANIMALS
#845GENOMIC EDITING OF PRION DISORDER-RELATED GENES IN ANIMALS
#846GENOMIC EDITING OF GENES INVOLVED IN SECRETASE-ASSOCIATED DISORDERS
#847GENOMIC EDITING OF GENES INVOLVED IN AUTISM SPECTRUM DISORDERS
#848GENOMIC EDITING OF GENES INVOLVED IN AMYOTROPHYIC LATERAL SCLEROSIS DISEASE
#849GENOMIC EDITING OF NEURODEVELOPMENTAL GENES IN ANIMALS
#850Genetically modified rat comprising a cytokine gene disruption and exhibiting a greater susceptibility to a cytokine-mediated autoimmune and/or inflammatory disease
#851GENOMIC EDITING OF GENES INVOLVED WITH PARKINSON'S DISEASE
#852RABBIT GENOME EDITING WITH ZINC FINGER NUCLEASES
#853GENOMIC EDITING OF GENES INVOLVED IN CARDIOVASCULAR DISEASE
#854METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
#855GENOMIC EDITING OF GENES INVOLVED IN INFLAMMATION
#856CANINE GENOME EDITING WITH ZINC FINGER NUCLEASES
#857GENOME EDITING OF SENSORY-RELATED GENES IN ANIMALS
#858GENOME EDITING OF GENES ASSOCIATED WITH TRINUCLEOTIDE REPEAT EXPANSION DISORDERS IN ANIMALS
#859GENOME EDITING OF NEUROTRANSMISSION-RELATED GENES IN ANIMALS
#860Methods for inhibiting angiogenesis using EGFL8 antagonists
#861Animal Model and Use of 17Beta-Hydroxysteroid Dehydrogenase Type 7 in the Diagnosis of Anencephaly
#862Methods and compositions for mitochondrial replacement therapy
#863Method of identifying a compound for preventing and/or treating an autoimmune disease
#864REGULATION OF CARDIAC CONTRACTILITY AND HEART FAILURE PROPENSITY
#865METHODS FOR PRODUCTION OF ATRIAL PROGENITORS AND THEIR DIFFERENTIATION INTO SMOOTH MUSCLE CELLS AND CARDIOMYOCYTES
#866Transgenic trasnchromosomal rodents for making human antibodies
#867Knockout mice for a P450 gene cluster
#868Non-human gene-disrupted animal with disrupted ADAM11 gene
#869Uses of Sperm Membrane Protein OBF
#870Method of expanding human hepatocytes in vivo
#871Animal Model Based on Targeted Apoptosis for the Study of Genetic Diseases Such as Parkinson's Disease
#872STROMAL INTERACTING MOLECULE KNOCKOUT MOUSE AND USES THEREOF
#873Transgenic non-human animals for pharmacological and toxicological studies
#874GDE Compositions and Methods
#875TREATMENT OF FIBROSES AND LIVER DISORDERS
#876ACE2 activation for treatment of heart, lung and kidney disease and hypertension
#877Inhibitors of Caspase I-Dependent Cytokines in the Treatment of Neurodegenerative Disorders
#878Adropin deficient mice and uses thereof
#879MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE QPCTL-GENE
#880Transgenic mouse with a homozygous mutation in the CMAH gene
#881Transgenic non-human animals for producing chimeric antibodies
#882Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes
#883Transgenic Zebrafish Models for Neurodegenerative Diseases
#884METHOD OF SCREENING PTP ZETA ACTIVITY PROMOTER OR INHIBITOR
#885Micro-RNA family that modulates fibrosis and uses thereof
#886Glycine N-methyltransferase (GNMT) Animal model and use thereof
#887Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling
#888MOUSE MODEL FOR DEPRESSION, SCHIZOPHRENIA AND ALZHEIMER'S DISEASE
#889METHODS, COMPOSITIONS AND TRANSGENIC MODELS RELATED TO THE INTERACTION OF T-CADHERIN AND ADIPONECTIN
#890COMPOSITIONS AND METHODS FOR MODULATING S-NITROSOGLUTHIONE REDUCTASE
#891Mouse models with enhanced essential tremor and preparation method thereof
#892Properdin Modulation of Alternative Pathway and Uses Thereof
#893SHIP-deficiency to increase megakaryocyte progenitor production
#894Knockin mouse with a disruption in a PXR gene expressing human PXR
#895Remedy for the treatment of cardio-vascular diseases or disorders
#896Regulator of ephrin-Eph receptor signaling and mouse having abnormal ephrin-Eph receptor signaling mechanisms
#897Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer and screening methods to identify same
#898GRP78 AND TUMOR ANGIOGENESIS
#899Novel Neurological Function of mPKCI
#900Transgenic mice for assessing drug metabolism and toxicity